DrugPatentWatch Database Preview
Remdesivir - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for remdesivir and what is the scope of freedom to operate?
Remdesivir
is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.Remdesivir has two hundred and forty-five patent family members in forty-five countries.
One supplier is listed for this compound.
Summary for remdesivir
| International Patents: | 245 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 14 |
| Clinical Trials: | 75 |
| Patent Applications: | 21 |
| What excipients (inactive ingredients) are in remdesivir? | remdesivir excipients list |
| DailyMed Link: | remdesivir at DailyMed |
Recent Clinical Trials for remdesivir
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Daewoong Pharmaceutical Co. LTD. | Phase 3 |
| University of Sao Paulo | Phase 3 |
| Conselho Nacional de Desenvolvimento Científico e Tecnológico | Phase 3 |
US Patents and Regulatory Information for remdesivir
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Gilead Sciences Inc | VEKLURY | remdesivir | SOLUTION;INTRAVENOUS | 214787-002 | Oct 22, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Gilead Sciences Inc | VEKLURY | remdesivir | POWDER;INTRAVENOUS | 214787-001 | Oct 22, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for remdesivir
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2017534614 | Start Trial |
| Portugal | 2595980 | Start Trial |
| Japan | 2014012739 | Start Trial |
| Israel | 208701 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for remdesivir
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2937350 | PA2020539 | Lithuania | Start Trial | PRODUCT NAME: REMDESIVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/20/1459 20200703 |
| 2937350 | LUC00193 | Luxembourg | Start Trial | PRODUCT NAME: REMDESIVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1459 20200703 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
